Pancreatic cancer
Conditions
Sponsors
Beijing Chaoyang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 80 years; 2. Imaging-confirmed (CT/MRI) borderline resectable pancreatic cancer (BRPC), meeting any of the following criteria: (1) Tumor contact with the superior mesenteric vein (SMV) or portal vein (PV) exceeding 180°, or contact = 180° accompanied by venous contour irregularity or thrombosis; (2) Presence of limited arterial involvement; (3) Degree of vascular invasion consistent with the definition of BRPC in the 8th edition of the AJCC Cancer Staging Manual; 3. Received at least one of the following standardized treatment strategies: (1) Radical resection combined with invaded vascular resection + end-to-end anastomosis after standardized neoadjuvant chemotherapy (e.g., FOLFIRINOX, gemcitabine plus nab-paclitaxel, etc.); (2) Radical resection combined with invaded vascular resection and allogeneic vascular replacement; 4. Complete preoperative clinical data, laboratory biochemical indicators (e.g., CA19-9, CEA), and preoperative CT images were available.
Exclusion criteria
Exclusion criteria: 1. Preoperative imaging or postoperative pathology confirmed distant metastasis; 2. Poor quality of imaging data, insufficient for radiomic feature analysis; 3. Received radiotherapy prior to treatment; 4. Complicated with other primary malignant tumors or severe systemic diseases (e.g., advanced cardiac insufficiency, severe hepatic or renal insufficiency); 5. Death due to other non-pancreatic cancer-related causes or loss to follow-up during the follow-up period; 6 Participation in concurrent interventional clinical trials, where intervention measures may affect prognostic assessment; 7. Others: e.g., major ethical issues or lack of informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse-Free Survival;Distribution of Individualized Treatment Recommendation Outputs;Clinical Adoption and Consistency; | — |
Countries
China
Contacts
Public ContactLang Ren
Beijing Chaoyang Hospital, Capital Medical University
Outcome results
None listed